Abstract Among myeloid leukemias, the acute promyelocytic leukemia (APL) was found to be specifically sensitive to all-trans retinoic acid (ATRA), almost all APL patients respond to ATRA therapy. The ATRA induces remission of APL patients by stimulating the differentiation of the leukemia cells. However, with the long-term application of ATRA alone, ATRA resistance has become one of the main causes of chemotherapy failure in the patients with acute promyelocytic leukemia. At present, the mechanism of ATRA-resistance is not completely clear, this review discusses the mechanism of drug-resistance in terms of signal pathways, genes, proteins and enzyme.
题目: 急性早幼粒细胞白血病对全反式维甲酸耐药机制的研究进展.
摘要: 在髓系白血病中，急性早幼粒细胞白血病（acute promyelocytic leukemia，APL）对全反式维甲酸（all-trans retinoic acid，ATRA）特别敏感。几乎所有APL患者对ATRA治疗都有反应，ATRA通过刺激白血病细胞分化，诱导APL患者缓解。然而，随着长期单用ATRA，ATRA耐药已成为APL患者化疗失败的主要原因之一。目前，对ATRA耐药机制尚不完全清楚，本文将从信号通路、基因、蛋白和酶问题来阐述其耐药机制.